Junguo Cao

Heidelberg University — Germany

Medicine · Health Sciences

11h-index501citations39works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Meningioma and schwannoma management(13), Multiple Myeloma Research and Treatments(7), Neurofibromatosis and Schwannoma Cases(7), Glioma Diagnosis and Treatment(6), Protein Degradation and Inhibitors(5)

Publications39 total

Drug Screening on Tumor Organoids Exposes Therapeutic Vulnerabilities of Meningiomas to HDAC1/2i Panobinostat
Zenodo (CERN European Organization for Nuclear Research)·2026Open Access
Drug Screening on Tumor Organoids Exposes Therapeutic Vulnerabilities of Meningiomas to HDAC1/2i Panobinostat
Zenodo (CERN European Organization for Nuclear Research)·2026Open Access
Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas
2025Open Access
Supplementary Figures1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas
2025Open Access
Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug Testing
Cells·2025· 1 citedOpen Access
Personalized Medicine for Meningiomas: Drug Screening on Tumor Organoids Exposes Therapeutic Vulnerabilities to HDAC1/2i Panobinostat
2024· 2 citedOpen Access
DDDR-22. USE OF BIOPSY-DERIVED TUMOR ORGANOIDS FOR PERSONALIZED DRUG TESTING IN RECURRENT GLIOBLASTOMA
Neuro-Oncology·2024Open Access
Developing a nomogram based on SEER database for predicting prognosis in choroid plexus tumors
Scientific Reports·2024· 2 citedOpen Access
Epidemiology and survival of non-malignant and malignant meningiomas in middle-aged females, 2004-2018
Frontiers in Oncology·2023· 11 citedOpen Access
Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas
2023Open Access
Data from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas
2023Open Access
Supplementary Figures1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas
2023Open Access
Supplementary Figures1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas
2023Open Access
Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas
2023Open Access
Data from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas
2023Open Access
Epidemiology and risk stratification of low-grade gliomas in the United States, 2004-2019: A competing-risk regression model for survival analysis
Frontiers in Oncology·2023· 15 citedOpen Access
MODL-35. A NOVEL PATIENT-DERIVED TUMOR ORGANOID MODEL IDENTIFIES HDACI PANOBINOSTAT AS HIGHLY EFFECTIVE DRUG IN MENINGIOMAS
Neuro-Oncology·2022Open Access
MODL-04. ESTABLISHMENT OF A RELIABLE GLIOBLASTOMA TUMOR-ORGANOID PLATFORM ENABLES AUTOMATED HIGH-THROUGHPUT DRUG SCREENING ADVANCING PERSONALIZED MEDICINE
Neuro-Oncology·2022· 1 citedOpen Access
TGF-β2 levels in the aqueous humor are elevated in the second eye of high myopia within two weeks after sequential cataract surgery
Scientific Reports·2022· 12 citedOpen Access
Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas
Clinical Cancer Research·2022· 15 cited
page 1 of 2Next →

Frequent Co-authors

Gerhard Jungwirth(21), Rolf Warta(19), Christel Herold‐Mende(19), Andreas Unterberg(17), Amir Abdollahi(17), Tao Yu(13), Mahmoud Moustafa(13), Montadar Alaa Eddine(11), Haiyan Huang(10), Fang Liu(9), Chaochao Zhang(6), Zhixin Zhan(6), Yuxue Sun(5), Weijia Yan(5), Catharina Lotsch(5), Sandro M. Krieg(5), Guihong Li(4), Xinyu Hong(4), Lena Jassowicz(4), Adrian Paul(4)